NASDAQ:CASI - CASI Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.60 +0.09 (+2.56 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$3.60
Today's Range$3.45 - $3.65
52-Week Range$2.73 - $8.89
Volume262,140 shs
Average Volume209,569 shs
Market Capitalization$343.03 million
P/E Ratio-20.00
Dividend YieldN/A
Beta1.19
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer. The company's late-stage clinical drug candidates, including EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma; MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; and ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma. It also offers a portfolio of 25 U.S. food and drug administration-approved abbreviated new drug applications and 1 abbreviated new drug applications. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.55 per share

Profitability

Net Income$-10,770,000.00

Miscellaneous

Employees51
Market Cap$343.03 million
OptionableNot Optionable

CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc (NASDAQ:CASI) issued its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.06. View CASI Pharmaceuticals' Earnings History.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for CASI Pharmaceuticals.

What price target have analysts set for CASI?

1 brokerages have issued 12 month price targets for CASI Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate CASI Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 94.4% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.

What is the consensus analysts' recommendation for CASI Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.

Has CASI Pharmaceuticals been receiving favorable news coverage?

Headlines about CASI stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CASI Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of CASI Pharmaceuticals' key competitors?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the folowing people:
  • Dr. Wei-Wu He, Exec. Chairman (Age 54)
  • Dr. Ken Keyong Ren, CEO & Director (Age 60)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
  • Dr. Alexander A. Zukiwski, Chief Medical Officer (Age 62)
  • Mr. George Chi, Chief Financial Officer

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.98%), Wellington Shields Capital Management LLC (1.24%), Wellington Shields & Co. LLC (1.13%), Northern Trust Corp (0.63%), Geode Capital Management LLC (0.61%) and Alps Advisors Inc. (0.23%). Company insiders that own CASI Pharmaceuticals stock include China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, BlackRock Inc., Northern Trust Corp and MetLife Investment Advisors LLC. View Insider Buying and Selling for CASI Pharmaceuticals.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was purchased by a variety of institutional investors in the last quarter, including Wellington Shields Capital Management LLC, Wellington Shields & Co. LLC, Geode Capital Management LLC, Alps Advisors Inc., Raymond James Financial Services Advisors Inc., Rhumbline Advisers, Bank of New York Mellon Corp and Bank of America Corp DE. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $3.60.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $343.03 million. The biotechnology company earns $-10,770,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. CASI Pharmaceuticals employs 51 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel